Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.

Funding Alexandria Venture Investments, the venture capital arm of real estate investment trust Alexandria Real Estate Equities, took part in a $76m series A round yesterday for Pheast Therapeutics, a US-based cancer drug developer spun out of Stanford University. Catalio Capital Management and Arch Venture Partners co-led the round, which also featured Risk and Reward…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.